Target of rapamycin (TOR) inhibition in renal transplantation: Clinical uses in various populations. Introduction.
Hricik
D E
DE
Division of Nephrology, Case Western Reserve University School of Medicine, Transplantation Services, University Hospitals of Cleveland, Cleveland, OH 44106, USA. deh5@po.cwru.edu
D044383:Black People / Q000235:genetics; D065095:Calcineurin Inhibitors; D006084:Graft Rejection / Q000517:prevention & control; D006085:Graft Survival / Q000187:drug effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D020123:Sirolimus / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D020123:Sirolimus